Alder BioPharmaceuticals (Alder BioPharmaceuticals) Total Debt per Share : $2.31 (As of Jun. 2019)

View and export this data going back to 2014. Start your Free Trial

What is Alder BioPharmaceuticals Total Debt per Share?

$2.31 (As of Jun. 2019)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Alder BioPharmaceuticals's Total Debt Per Share for the quarter that ended in Jun. 2019 was $2.31.

Alder BioPharmaceuticals Total Debt per Share Historical Data

The historical data trend for Alder BioPharmaceuticals's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alder BioPharmaceuticals Total Debt per Share Chart

Alder BioPharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Total Debt per Share

Get a 7-Day Free Trial

2.66

Alder BioPharmaceuticals Quarterly Data
	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19
Total Debt per Share	Get a 7-Day Free Trial															2.58	2.62	2.66	2.29	2.31

Alder BioPharmaceuticals Total Debt per Share Calculation

Alder BioPharmaceuticals's Total Debt Per Share for the fiscal year that ended in Dec. 2018 is calculated as:

Total Debt Per Share	=	(Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation)	/	Shares Outstanding (EOP)
	=	(182.10	+	0.00)	/	68.41
	=	2.66

Alder BioPharmaceuticals's Total Debt Per Share for the quarter that ended in Jun. 2019 is calculated as:

Total Debt Per Share	=	(Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation)	/	Shares Outstanding (EOP)
	=	(192.38	+	0.98)	/	83.61
	=	2.31

Alder BioPharmaceuticals Total Debt per Share Related Terms

Thank you for viewing the detailed overview of Alder BioPharmaceuticals's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Alder BioPharmaceuticals (Alder BioPharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alder BioPharmaceuticals Inc (NAS:ALDR) » Definitions » Total Debt per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

11804 North Creek Parkway South, Bothell, WA, USA, 98011

Website

http://www.alderbio.com

Alder BioPharmaceuticals is a biotechnology company that seeks to discover, develop, and commercialize therapeutic antibodies. The company's antibody platform seeks to maximize efficacy, as well as speed of onset and durability of therapeutic response. Alder's product pipeline addresses diseases where patients have limited medical options or where current medical options may not meet the needs of a substantial number of patients. The company operates in two geographic regions: the United States and Australia. The vast majority of the Alder's assets are located in the United States, where the vast majority of its revenue is also generated.

Executives

Paul Rutherford Carter	director	SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF
H Lundbeck A S	10 percent owner	9 OTTILIAVEJ DK 2500 VALBY, COPENHAGEN, DENMARK G7 00000
Clay B Siegall	director	21823 30TH DR SE, BOTHELL WA 98021
Paul Streck	officer: Chief Medical Officer	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Wendy L Yarno	director
Carlos Campoy	officer: Chief Financial Officer	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Robert Azelby	director, officer: President and CEO	307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Heather Preston	director	C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, FORT WORTH TX 76102
Jeremy Green	director	45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc	director	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Paul B Cleveland	director	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Alan Bruce Montgomery	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Mark James Litton	officer: Chief Business Officer	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Deepika Pakianathan	director	160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Eric G Carter	officer: Interim Chief Medical Officer	C/O KING PHARMACEUTICALS, INC., 501 FIFTH STREET, BRISTOL TN 37620